The University of Oxford plans to test its COVID-19 vaccine in children for the first time, becoming the latest vaccine developer to assess whether its coronavirus shot is effective in young people.
The trial announced on Saturday seeks to recruit 300 volunteers between the ages of 6 and 17, with up to 240 receiving the COVID-19 vaccine and the remainder a control meningitis vaccine.
Andrew Pollard, chief researcher on the Oxford vaccine trial, said that while most children don’t get severely ill from COVID-19, “it is important to establish the safety and immune response to the vaccine in children and young people as some children may benefit from vaccination.’’
Regulators in more than 50 countries have authorized widespread use of the Oxford vaccine, which is being produced and distributed by AstraZeneca, for use in people over the age of 18.
Other drug companies are also testing the COVID-19 vaccines in children. Pfizer, whose vaccine has already been authorized for use in people 16 and older, began testing its shot in children as young as 12 in October.
Moderna in December began testing its vaccine on children as young as 12.
Mr. Pollard said the Oxford trial should help policymakers decide whether at some point in the future they want to extend mass vaccination programs to children.
You have reached your limit for free articles this month.
Subscription Benefits Include
Today's Paper
Find mobile-friendly version of articles from the day's newspaper in one easy-to-read list.
Unlimited Access
Enjoy reading as many articles as you wish without any limitations.
Personalised recommendations
A select list of articles that match your interests and tastes.
Faster pages
Move smoothly between articles as our pages load instantly.
Dashboard
A one-stop-shop for seeing the latest updates, and managing your preferences.
Briefing
We brief you on the latest and most important developments, three times a day.
Support Quality Journalism.
*Our Digital Subscription plans do not currently include the e-paper, crossword and print.
A letter from the Editor
Dear subscriber,
Thank you!
Your support for our journalism is invaluable. It’s a support for truth and fairness in journalism. It has helped us keep apace with events and happenings.
The Hindu has always stood for journalism that is in the public interest. At this difficult time, it becomes even more important that we have access to information that has a bearing on our health and well-being, our lives, and livelihoods. As a subscriber, you are not only a beneficiary of our work but also its enabler.
We also reiterate here the promise that our team of reporters, copy editors, fact-checkers, designers, and photographers will deliver quality journalism that stays away from vested interest and political propaganda.
Suresh Nambath
